Alcon Inc (ALC)
78.21
-1.36
(-1.71%)
USD |
NYSE |
Apr 25, 10:11
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 38.58B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 8.89% |
| Valuation | |
| PE Ratio | 39.90 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.104 |
| Price to Book Value | 1.870 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.2652 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2293 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 37.19% |
Profile
| Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |
| URL | https://www.alcon.com |
| Investor Relations URL | https://investor.alcon.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | May. 09, 2024 (est.) |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | May. 14, 2024 |
| Last Ex-Dividend Date | May. 10, 2023 |
Ratings
Profile
| Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |
| URL | https://www.alcon.com |
| Investor Relations URL | https://investor.alcon.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | May. 09, 2024 (est.) |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | May. 14, 2024 |
| Last Ex-Dividend Date | May. 10, 2023 |